10-Q: Astrana Health Reports Strong Q2 Growth Post-Acquisition

Astrana Health, Inc. (ASTH) announced robust financial results for the second quarter ended June 30, 2026, showcasing significant revenue increases and improved net income, largely driven by the strategic acquisition of Prospect Medical Holdings.

Summary

• Astrana Health reported a substantial increase in revenue for the second quarter of 2026, reaching $972.5 million, a 49% rise from $654.8 million in the prior year period.
• Net income attributable to Astrana Health, Inc. more than doubled to $19.7 million from $9.4 million in the same quarter last year.
• The acquisition of Prospect Medical Holdings, completed in July 2025, significantly contributed to the revenue growth, adding $281.5 million in the current quarter.
• Cost of services increased by 51% to $868.5 million, largely due to the Prospect acquisition and increased participation in value-based care models.
• Interest expense more than doubled to $16.0 million, primarily due to increased borrowings to finance the Prospect acquisition.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth driven by a significant acquisition and improved profitability. The company demonstrates solid operational performance and a healthy outlook.

Positives

• Revenue increased by 49% to $972.5 million for the three months ended June 30, 2026, compared to $654.8 million in the prior year.
• Net income attributable to Astrana Health, Inc. grew by 109% to $19.7 million for the three months ended June 30, 2026, from $9.4 million in the prior year.
• The acquisition of Prospect Medical Holdings contributed $281.5 million in revenue for the quarter.
• Adjusted EBITDA increased by 43% to $68.9 million for the three months ended June 30, 2026.
• Care Enablement segment revenue more than doubled, increasing by 109% to $85.6 million, with operating income rising significantly.
• Care Delivery segment revenue increased by 95% to $74.7 million, driven by Prospect's inclusion and increased patient volume.

Negatives

• Interest expense increased by 117% to $16.0 million due to higher borrowings for the Prospect acquisition.
• Operating income for the Care Partners segment decreased by 14% to $42.9 million, attributed to higher claims expenses.
• Operating loss for the Care Delivery segment was $3.0 million, a decrease from an operating income of $2.1 million in the prior year.
• Net loss attributable to non-controlling interests increased to $1.3 million from $0.8 million, primarily due to losses in APC.

Risks

• The company identified a material weakness in internal control over financial reporting associated with the accounting for business combinations, which has not been remediated.
• The company's business is subject to complex laws and regulations governing healthcare, including Medicare and Medicaid programs, with potential for fines, penalties, or exclusion from programs.
• The company faces risks related to interpretations of payer and provider contracts, which could lead to disputes over amounts due.
• Standby letters of credit and surety bonds totaling $27.5 million and $57.2 million, respectively, are in place for regulatory compliance.
• The company is involved in various legal proceedings, though management believes the ultimate liability will not be material.

Future Outlook

The company believes it has sufficient liquidity to fund its operations through at least the next 12 months and the foreseeable future. The company has a current shelf registration statement allowing for future offerings of various securities.

Management Comments

• The acquisition of Prospect significantly expanded the Company's provider network and enhanced its ability to offer increased access, quality, and value to its members.
• The Company is a leading physician-centric, AI-powered, risk-bearing healthcare management company.
• We believe we have sufficient liquidity to fund our operations through at least the next 12 months and the foreseeable future.

Industry Context

StockSavvy.ai notes that Astrana Health's performance reflects broader industry trends in healthcare consolidation and the increasing adoption of value-based care models. The significant revenue growth post-acquisition highlights the strategic importance of M&A in expanding market reach and service offerings within the managed care sector.

Comparison to Industry Standards

• Astrana Health's revenue growth of 49% for the quarter significantly outpaces the average growth rates seen in the broader healthcare services sector, which has been more moderate.
• The company's focus on value-based care and risk-bearing models aligns with industry shifts away from fee-for-service, aiming for better cost control and patient outcomes.
• The increase in depreciation and amortization due to acquisitions is a common trend among companies undergoing significant M&A activity in the healthcare industry.
• The company's Adjusted EBITDA margin of 7% is within a reasonable range for healthcare management companies, though specific comparisons depend on the sub-sector and business model.

Legal Proceedings

• The company is involved in various legal proceedings arising in the normal course of business. Management believes the ultimate liability will not be material to financial position, results of operations, or cash flows.
• A specific arbitration proceeding involving Community Family Care Health Plan, Inc. (CFC HP) was resolved by settlement and dismissed in February 2026, with a total settlement payment of $13.0 million.

Related Party Transactions

• Payments made to equity method investees for services such as provider, call center, and credentialing services.
• Rent expenses incurred from properties managed by Allied Pacific Holdings Investment Management, LLC, in which two directors have ownership and one serves as CEO/CFO.
• Agreements with AHMC for hospital and inpatient-related services, including a risk-sharing agreement for hospital pools.
• Payments made to APC board members for provider services, some of whom also serve as Astrana board members and/or officers.

Stakeholder Impact

• Shareholders benefit from increased revenue and net income, reflecting improved company performance and potential for future value appreciation.
• Employees may see continued investment in operational growth and potential for stock-based compensation, though a material weakness in internal controls could pose risks.
• Patients are expected to benefit from expanded access and quality of care due to the acquisition and the company's value-based care model.
• Creditors are subject to the company's debt obligations, with interest expense increasing due to financing for the acquisition.

Next Steps

• Continue to integrate the Prospect acquisition and realize synergies.
• Focus on managing claims expenses and optimizing value-based care models.
• Monitor and remediate the identified material weakness in internal control over financial reporting.
• Leverage the existing shelf registration statement for potential future capital raises if needed.

Key Dates

Recommendation

The company shows strong growth driven by a significant acquisition, with improved profitability and positive segment performance. However, the increase in debt, rising interest expenses, and the unaddressed material weakness in internal controls warrant a cautious 'hold' rating until these factors are better managed and integrated.

Keywords

Healthcare Management, Value-Based Care, Capitation Revenue, Medicare Advantage, Medicaid, Physician Network, Acquisition, Prospect Medical Holdings